Research programme: antibody therapeutics - Genmab

Drug Profile

Research programme: antibody therapeutics - Genmab

Alternative Names: Duobody-CD3-CD20; Hexabody®-DR5/DR5

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genmab
  • Class Antibodies; Antineoplastics
  • Mechanism of Action CD20 antigen inhibitors; CD3 antigen inhibitors; Immunostimulants; TRAIL receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Infections

Most Recent Events

  • 02 Nov 2016 Preclinical trials in Cancer in Denmark (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for research development in Cancer in Denmark (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for research development in Infections in Denmark (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top